Measuring PD-L1 expression on CTCs through a simple blood draw represents a low risk approach to initial patient stratification with minimal cost and gives us an opportunity to monitor PD-L1 expression of patient tumor cells over the course of the disease. The gene discussed is CD274; the disease is neoplasm.